Instituto de Reumatologia | Mendoza, Argentina

Research site

(Unclaimed)

Location

CORDOBA 292 PB, Mendoza, Mendoza, Argentina

Site insights

Top conditions

Top treatments

BIIB059

Litifilimab

M5049

Filgotinib

M2951

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 7 total trials

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling

Subacute Cutaneous Lupus Erythematosus

Chronic Cutaneous Lupus Erythematosus

Drug: Litifilimab

Drug: Placebo

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (TOPAZ-2)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling

Lupus Erythematosus, Systemic

Drug: Placebo

Drug: Litifilimab

An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (EMERALD)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Invitation-only

Systemic Lupus Erythematosus (SLE)

Drug: Litifilimab-matching placebo

Drug: Litifilimab

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis (FINCH 4)

The primary objective of this study is to evaluate the long-term safety and tolerability of filgotinib in participants who have completed one of the...

Active, not recruiting

Rheumatoid Arthritis

Drug: Filgotinib

Drug: Placebo to match filgotinib

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus...

Enrolling

Systemic Lupus Erythematosus

Drug: M5049 medium dose

Drug: M5049 low dose

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms